VK2735: The Oral Weight Loss Pill That Lost 26 Pounds in 13 Weeks

An oral weight loss pill that melts 26 pounds in 13 weeks. No injections. No refrigeration. No pharmacy compounding drama. That's what Viking Therapeutics just showed at the European Congress on Obesity in Istanbul — and the data has the entire metabolic drug industry paying attention.

VK2735 is a dual GLP-1/GIP receptor agonist — the same mechanism behind tirzepatide (Mounjaro/Zepbound) — but Viking is developing it as a once-daily tablet. If Phase 3 trials deliver, this could become the first oral dual incretin agonist to reach the market. Here's what the data actually shows.

The Data: 12.2% Weight Loss in Just 13 Weeks

Viking presented results from its Phase 2 VENTURE-Oral Dosing trial at ECO 2026 in May. The study enrolled 280 adults with obesity (average BMI 37 kg/m², average age 51) and randomized them to once-daily oral VK2735 at doses of 15 mg, 30 mg, 60 mg, 90 mg, or 120 mg, or placebo, for 13 weeks.

The results were striking. At the highest dose (120 mg), participants lost an average of 12.2% of their body weight — that's 26.6 pounds for someone starting at 218 pounds. The placebo group lost just 1.3%. The weight loss was dose-dependent, statistically significant at every dose above 15 mg (p < 0.0001), and showed no signs of plateauing by week 13.

The responder rates tell the real story. At the 120 mg dose, 80% of participants lost at least 10% of their body weight. Across all active doses, 97% lost at least 5%. Compare that to placebo, where only 5-10% hit those thresholds.

Why Dual Agonism Matters

VK2735 works by simultaneously activating two incretin receptors: GLP-1 and GIP. GLP-1 agonists like semaglutide (Ozempic) suppress appetite and slow gastric emptying. GIP agonists add a second layer — they enhance insulin action and may actually improve the tolerability profile of GLP-1 drugs.

This dual mechanism is the same approach behind tirzepatide, which showed up to 20.9% weight loss in the SURMOUNT-1 trial over 72 weeks. The key difference? VK2735 comes in a pill. No needles. No cold chain storage. No injection site reactions. For the millions of people who balk at weekly injections, that's a meaningful distinction.

There's also a strategic wrinkle. Viking is developing both oral and subcutaneous formulations of VK2735, using the same active molecule. In theory, a patient could start on injections for faster results, then switch to the oral tablet for maintenance — all without changing their drug. No other company is pursuing this exact approach.

The Safety Picture

The side effect profile looks manageable. Most adverse events were gastrointestinal — nausea, diarrhea, constipation, the usual GLP-1 suspects — and they were predominantly mild to moderate. Importantly, they tended to occur early in treatment and resolve with continued dosing, which tracks with what we see across the entire incretin class.

What we don't know yet is the long-term picture. Thirteen weeks is too short to assess cardiovascular outcomes, bone density effects, or the muscle loss question that hangs over all GLP-1 drugs. The Phase 3 VANQUISH program (78 weeks for the injectable) will provide much more data on those fronts.

VENTURE-Oral Phase 2 Results at a Glance

Dose → Mean Weight Loss → % Losing ≥10% → p-value vs Placebo

Placebo: -1.3% | 5% achieved ≥10% loss | —

15 mg: -2.3% | 8% achieved ≥10% loss | Not significant

30 mg: -7.0% | 35% achieved ≥10% loss | p < 0.0001

60 mg: -8.7% | 40% achieved ≥10% loss | p < 0.0001

90 mg: -11.1% | 59% achieved ≥10% loss | p < 0.0001

120 mg: -12.2% | 80% achieved ≥10% loss | p < 0.0001

What This Means for the Weight Loss Landscape

The oral GLP-1 market is about to get very crowded. Novo Nordisk already sells oral semaglutide (Rybelsus) for diabetes, and their higher-dose obesity version is in late-stage trials. Eli Lilly has orforglipron, a non-peptide oral GLP-1 agonist, in Phase 3. Pfizer, AstraZeneca, and Roche all have oral candidates.

VK2735's differentiator is the dual mechanism. Every other oral candidate in late-stage development is a GLP-1 mono-agonist. If Viking can show that dual agonism delivers superior weight loss in an oral format — and the Phase 2 data suggests it can — they'd own a unique position in the market.

The timeline matters. Viking plans to start Phase 3 oral trials in Q3 2026. The injectable VANQUISH-1 and VANQUISH-2 trials (78 weeks) are already fully enrolled. If everything goes perfectly, we're looking at 2028-2029 for potential FDA approval. That's aggressive, but Viking has been hitting their milestones.

How VK2735 Stacks Up

Direct comparisons are unfair — different trial designs, durations, and populations. But here's the rough landscape: semaglutide (Wegovy) showed ~14.9% weight loss at 68 weeks. Tirzepatide (Zepbound) hit ~20.9% at 72 weeks. Retatrutide (Eli Lilly's triple agonist) showed ~24.2% at 48 weeks in Phase 2.

VK2735's 12.2% at just 13 weeks is impressive because the curve hadn't plateaued. Extrapolate that trajectory over 68-72 weeks and you're potentially looking at numbers competitive with tirzepatide. But extrapolation is dangerous in clinical trials — we need the Phase 3 data to know for sure.

What the Community Is Saying

On Reddit's r/tirzepatidecompound, users who've experienced the dual agonist mechanism through tirzepatide consistently report it as superior to semaglutide monotherapy. One user who switched from semaglutide to tirzepatide reported losing 80 pounds and actually improving muscle mass — a claim that rarely appears with GLP-1 monotherapy.

The appetite for oral alternatives is intense. Multiple community members describe injection fatigue after months of weekly shots. The idea of a once-daily pill with comparable efficacy generates significant excitement, even among people currently doing well on injectable tirzepatide.

The Oria Take

VK2735 represents the next logical step in incretin therapy: same proven dual mechanism as tirzepatide, delivered as a daily tablet. The Phase 2 data is genuinely impressive for a 13-week oral trial, and the dual-formulation strategy (same molecule, two delivery options) is smart pharmacology.

For the peptide therapy space, this matters in two ways. First, it validates the dual GLP-1/GIP mechanism as the dominant paradigm — this isn't a niche approach anymore, it's where the industry is heading. Second, the oral format could dramatically expand access. Injections are a barrier for many patients. Pills aren't.

We'll be watching the Phase 3 oral trial (planned Q3 2026) closely. If the Phase 3 data confirms what Phase 2 showed, VK2735 could be a game-changer for people who want tirzepatide-level results without the needle.

Evidence Grade: B+ — Strong Phase 2 data with clear dose-response and statistical significance. Short duration (13 weeks) and lack of long-term safety data prevent an A. Phase 3 trials will be definitive. Mechanism is validated by approved tirzepatide, but VK2735 itself is investigational and not available outside clinical trials.

This article is for informational purposes only and does not constitute medical advice. VK2735 is an investigational drug not approved by the FDA. It is not available by prescription, through compounding pharmacies, or for purchase. Always consult a qualified healthcare provider before starting any weight loss medication or peptide protocol. The information presented is based on published clinical trial data and may not reflect individual outcomes.